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Critical review of the safety assessment 
of titanium dioxide additives in food
Hans Christian Winkler1, Tina Notter2, Urs Meyer2 and Hanspeter Naegeli2*
Abstract 
Nanomaterial engineering provides an important technological advance that offers substantial benefits for appli-
cations not only in the production and processing, but also in the packaging and storage of food. An expanding 
commercialization of nanomaterials as part of the modern diet will substantially increase their oral intake worldwide. 
While the risk of particle inhalation received much attention, gaps of knowledge exist regarding possible adverse 
health effects due to gastrointestinal exposure. This problem is highlighted by pigment-grade titanium dioxide  (TiO2), 
which confers a white color and increased opacity with an optimal particle diameter of 200–300 nm. However, size 
distribution analyses showed that batches of food-grade  TiO2 always comprise a nano-sized fraction as inevitable 
byproduct of the manufacturing processes. Submicron-sized  TiO2 particles, in Europe listed as E 171, are widely used 
as a food additive although the relevant risk assessment has never been satisfactorily completed. For example, it is not 
possible to derive a safe daily intake of  TiO2 from the available long-term feeding studies in rodents. Also, the use of 
 TiO2 particles in the food sector leads to highest exposures in children, but only few studies address the vulnerability 
of this particular age group. Extrapolation of animal studies to humans is also problematic due to knowledge gaps 
as to local gastrointestinal effects of  TiO2 particles, primarily on the mucosa and the gut-associated lymphoid system. 
Tissue distributions after oral administration of  TiO2 differ from other exposure routes, thus limiting the relevance of 
data obtained from inhalation or parenteral injections. Such difficulties and uncertainties emerging in the retrospec-
tive assessment of  TiO2 particles exemplify the need for a fit-to-purpose data requirement for the future evaluation of 
novel nano-sized or submicron-sized particles added deliberately to food.
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Background
Potential applications of recent nanomaterial develop-
ments in the food sector include, for example, nano-
sized coatings of packaging materials to protect from 
mechanical damage or microbial contamination, thereby 
extending the shelf life. Nano-sized additives may also 
be deliberately incorporated in food to optimize prop-
erties such as taste, sensation, color, texture or consist-
ency. Nanomaterials may be employed to supplement 
food with vitamins in a highly bioavailable form and 
could contribute to prevent nutritional iron deficiency 
and anemia, affecting nearly 2 billion people worldwide 
[1–3]. Nano-sized materials may further provide mark-
ers of food freshness and quality, or allow for traceabil-
ity and the detection of pathogens or contaminants [4, 
5]. In contrast to these novel developments, submicron-
sized particles of titanium dioxide  (TiO2) have been used 
in the food sector for more than 50  years as a pigment 
to enhance the white color and opacity of foods like cof-
fee creamer, sauces, spreads, pastries, candies and edible 
ices. Also,  TiO2 confers brightness to toothpaste and is 
added to enhance the flavor of non-white foods (pro-
cessed fish, fruits, meat, vegetables, breakfast cereals, 
fermented soybean, soups and mustard) and to clear bev-
erages (beer, cider and wine) [6–9].
Currently, the annual consumption volume of  TiO2 par-
ticles reaches four million tons, which makes it the most 
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widely used pigment globally [10]. In the United States 
(US), the Food and Drug Administration allows up to 1% 
by weight of  TiO2 particles as a food colorant [11]. In the 
European Union (EU),  TiO2 is an authorized food addi-
tive (listed as E 171) at quantum satis, meaning that no 
maximum level is imposed as long as the additive is used 
in accordance with good manufacturing practice, i.e., at 
a level not higher than necessary to achieve the intended 
scope [12]. A comparison of use levels reported by the 
food industry show that the highest  TiO2 concentrations 
are expected in chewing gum (up to 16,000 mg/kg), food 
supplements delivered in a solid form (up to 12,000 mg/
kg), processed nuts (up to 7000 mg/kg) and ready-to-use 
salads and sandwich spreads (up to 3000  mg/kg) [13]. 
 TiO2 particles can, therefore, be viewed as a paradig-
matic case for the safety assessment of inorganic particles 
employed as food additive and comprising a nano-scale 
fraction.
The standard risk assessment procedure with 
risk = hazard × exposure, which includes hazard identifi-
cation, hazard characterization, exposure assessment and 
risk characterization, is also applicable to small inorganic 
particles in food. The prefix “nano” does not make a sub-
stance automatically harmful and possible adverse effects 
should be tested case-by-case. However, reductions in 
size may change the material characteristics as compared 
to larger particles or the same substance in solution. 
Nano-sized particles display an increased surface-to-
mass ratio that enhances their reactivity [14, 15]. Also, 
nanoparticles display an increased propensity to pene-
trate through cell membranes thus conferring the poten-
tial for trafficking across biological barriers including the 
intestinal mucosa [16–18]. In principle, a nanomaterial 
exists in different forms, i.e., with one dimension in the 
nano-scale (for example nano-films), two dimensions in 
the nano-scale (for example nano-rods) or, as for nano-
particles, all three dimensions in the nano-scale range. A 
European Commission Recommendation defines nano-
materials as natural, incidental or manufactured materi-
als, containing 50% or more of the particles, determined 
in a number-based size distribution, with at least one 
external dimension not exceeding 100 nm [19]. However, 
there is no scientific ground to defend such a strict size 
boundary in the identification of possible hazards, as one 
would rather expect a gradient in the capacity of eliciting 
adverse effects with changing particle dimensions. In any 
case, a final answer to the question of when a material 
becomes nano-sized has not been provided [20] and the 
above Recommendation is not yet adopted for regulatory 
purposes.
Until now, the health effects of  TiO2 particles have 
been studied mainly with regard to their uptake by inha-
lation [21–23]. The International Agency for Research 
on Cancer (IARC) concluded that there is inadequate 
evidence from epidemiological studies to assess whether 
 TiO2 dust causes cancer in humans, but that there is suf-
ficient evidence for carcinogenicity in experimental ani-
mals, based on the induction of respiratory tract tumors 
in rats after prolonged inhalation [24, 25]. Therefore, 
IARC classified  TiO2 as a Group 2B carcinogen [26]. 
Considering the widespread food-related uses, there is a 
pressing need to review the suitability of studies support-
ing the risk assessment of  TiO2 particles as food additive 
[27]. Comprehensive reviews on this topic have been 
provided inter alia by Shi et  al. [28], Heringa et  al. [29] 
and the Scientific Panel on Food Additives and Nutrient 
Sources added to Food (ANS Panel) [13]. The purpose 
of our contribution is to focus on data gaps and uncer-
tainties in relevant risk assessment studies covering the 
dietary uptake of  TiO2 particles.
TiO2 particle manufacture and their physicochemical 
properties
Although Ti is the ninth most abundant element in the 
earth’s crust, it never appears in a metallic state in nature. 
 TiO2, an odorless powder with a molecular weight of 
79.9  g/mol, also known as Ti(IV) oxide, constitutes the 
naturally occurring oxide [30, 31].  TiO2 minerals contain 
impurities such as iron, chromium, vanadium or zirco-
nium that confer a spectrum of different colors. Manu-
factured  TiO2 is, instead, a white powder commonly 
used as a pigment in ceramics, paints, coatings, plastics 
and paper due to its high refractive index. Pure  TiO2 
assembles in three crystal structures, i.e., anatase, rutile 
(with tetragonal coordination of Ti atoms) and brookite 
(with rhombohedral coordination of Ti atoms), but only 
anatase/rutile or mixtures of these two polymorphs are 
employed in food [32]. In addition, as a fourth form, 
amorphous  TiO2 has been described [33]. The surface of 
anatase crystals is considered to be more reactive than 
that of rutile counterparts, as indicated by their ability 
to generate reactive oxygen species in aqueous solutions 
when irradiated with ultraviolet (UV) light [34]. Also, 
anatase nanoparticles display a stronger adjuvant activ-
ity than rutile nanoparticles in an allergy model based on 
the intranasal sensitization of mice with ovalbumin [35]. 
Nonetheless, the anatase form is the most frequently 
used in the food sector [8, 36, 37].
Food-grade  TiO2 is manufactured from Ti minerals 
by either a sulfuric acid-based process, which can yield 
anatase, rutile or a mixture of both polymorphs depend-
ing on the reaction conditions, or a chlorine-based pro-
cess yielding only the rutile form [32]. Specifications for 
food use include a minimum purity of 99.0%, thus allow-
ing some contamination with arsenic, cadmium and mer-
cury (up to 1 mg/kg), antimony (up to 2 mg/kg) or lead 
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(up to 10 mg/kg). Also, food-grade  TiO2 may be coated 
with a small proportion (no more than 2% in total) of 
alumina and silica to enhance technological properties, 
for example to improve dispersion in host matrices [32, 
38]. All  TiO2 particles are insoluble in water, organic sol-
vents, hydrochloric acid and dilute sulfuric acid. They are 
highly stable to heat and remain unaffected by food pro-
cessing. Also, they are not or only minimally degraded 
or dissolved under conditions, including low pH, which 
mimic the gastrointestinal milieu [39, 40]. Such indigest-
ible particles, once released from the food matrix during 
their gastrointestinal transit, reach the intestinal mucosa 
raising the question of whether they might be prone to 
absorption and systemic distribution.
Optimal light scattering is needed to achieve the 
desired whitening effect. Therefore, food-grade  TiO2 
ideally displays a primary particle size of approximately 
half the wavelength of the light to be scattered [41], i.e., 
half of the 400–700-nm of the visible range. Accordingly, 
scattering of visible light is maximized in fine particles 
that are 200–300  nm in diameter. Ultrafine products 
are instead not suited for this purpose as they become 
transparent when their size remains below the 100-nm 
threshold [42]. Such nano-sized  TiO2 particles are often 
included at concentrations of up to 25% in cosmetic prep-
arations, including lip balms and sunscreens to protect 
from solar light by reflecting UV radiation away from the 
skin [43, 44]. As a consequence of the production process 
there is inevitably a broad size distribution that com-
prises nanoparticles with a primary size below 100  nm 
even when the mean diameter reaches 200–300  nm. In 
this respect, a frequently cited size distribution is the one 
determined by Weir et al. [6] using transmission electron 
microscopy (TEM), whereby 36% of particles by num-
ber were below the threshold of 100  nm. This data was 
derived from a single determination with one lot of E 171 
and, hence, is not representative for all  TiO2 on the mar-
ket. In a follow-up distribution analysis of five different 
food-grade  TiO2 samples by TEM, nano-sized particles 
occured with a frequency between 17 and 35% by num-
ber [8]. Studies by scanning electron microscopy (SEM) 
suggested that commercial E 171 materials contain ~ 10% 
of particles with dimensions below 100  nm [7]. Clearly, 
the outcome of particle size determinations varies with 
the method of measurement, whereby smaller diameters 
are generally reported from TEM measurements com-
pared for example to laser diffraction [13, 45]. Another 
relevant aspect is that, as illustrated in Fig. 1, suspended 
 TiO2 particles tend to aggregate/agglomerate to form 
larger clusters, although a majority of the individual 
particles may display a primary diameter < 100  nm. The 
term “aggregate” designates an assembly of particles held 
together by covalent or metallic bonds. Instead, “agglom-
erates” result from weak forces like van der Waals inter-
actions, hydrogen bonding, electrostatic attractions 
or adhesion by surface tensions. It is important not to 
equate the nanoparticle fraction measured by num-
ber with the same value by mass. The ANS Panel at the 
European Food Safety Authority (EFSA) proposes to use 
a proportion of 3.2% by mass to estimate the nano-sized 
Fig. 1 Example of food-grade  TiO2 particles (E 171). a A sample of food-grade anatase dispersed in  H2O was deposited on a copper grid coated 
with glow-discharged parlodion and analyzed by TEM as described [146, 147]. Scale bar, 100 nm. b Size distribution of the imaged food-grade 
 TiO2 particles. The diameter measured as longest distance across particles is 100 ± 24 nm (mean ± standard deviation) and 54% by number of the 
particles have a diameter < 100 nm
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fraction of E 171 for risk assessment considerations [13]. 
TEM analyses of  TiO2 particles in the coatings of chew-
ing gums revealed a nano-sized mass fraction of 4.2% on 
the average [45, 46]. This review only includes studies 
where  TiO2 test materials have been characterized with 
respect to their size preferably with indications on the 
primary particle diameter.
Human exposure
In the US, the dietary intake of  TiO2 was estimated 
at 1–2  mg/kg body weight per day for children under 
the age of 10  years and 0.2–0.7  mg/kg/day for other 
age groups. This dietary exposure in the United King-
dom (UK) population was estimated to be 2–3  mg/kg/
day for children and around 1  mg/kg/day for the other 
age groups [6]. The corresponding exposure values esti-
mated for the German population are between 0.5 and 
1  mg/kg/day in adults but reach ~ 2  mg/kg/day in chil-
dren [47]. To obtain dietary exposures across Europe, the 
ANS Panel at EFSA selected food categories for which 
the use of  TiO2 is authorized, and assumed that 60–80% 
by weight of these food items actually contain  TiO2 as an 
additive. Next, the ANS Panel used the EFSA Compre-
hensive European Food Consumption Database and the 
typical  TiO2 inclusion levels reported by industry (see 
background section above), as well as reported analyti-
cal results, to calculate chronic dietary exposures to  TiO2 
for different age groups. The highest values were found 
for children of 3–9 years where, depending on the dietary 
habits, the mean exposures were 0.9–8.8  mg/kg body 
weight per day with 95th percentiles of 2.4–30.2  mg/kg 
per day. Some relevant food categories (for example edi-
ble cheese rind) are not displayed in the Consumption 
Database and, as a consequence, could not be taken into 
account for the exposure estimate. Also, the contribution 
of the accidental swallowing of toothpaste or lip balms 
was not included in these calculations, possibly resulting 
in an underestimation of oral  TiO2 intake. Another study 
employed the Dutch National Food Consumption Survey 
and the  TiO2 concentrations in food products reported 
by industry [48]. Again, the highest exposure (median 
of 1.4 mg/kg body weight per day and 95th percentile of 
4.9 mg/kg) was found in children 2–6 years old. A parallel 
study also employed the Dutch National Food Consump-
tion Survey but used Ti and/or  TiO2 concentrations in 
food products and toothpaste as reported in the literature 
[36]. The calculations confirmed that the highest intake 
(median of 0.59 mg/kg body weight per day and 95th per-
centile of 1.29 mg/kg) is found in children 2–6 years old. 
The generally elevated exposure of children is attributed 
to their lower body mass and disproportionately higher 
consumption of  TiO2-containing products like pastries 
and candies [6, 13].
Determinants of intestinal uptake
After oral exposure, foreign particles released by diges-
tion from the food matrix encounter a layer of entero-
cytes, lining the intestinal tract, that are responsible for 
nutrient absorption. This digestive epithelium surface, 
in humans estimated to 30 m2 [49], presents a structural 
barrier to foreign materials that also secretes a protec-
tive layer of mucus. Indigestible particles like the ones 
consisting of  TiO2 may nevertheless gain entry into 
the underlying lamina propria by penetration across 
or between intact enterocytes. However, the digestive 
mucosa is additionally defended by the gut-associated 
lymphoid tissue (GALT), which is arranged into lym-
phoid follicles that, in the small intestine, aggregate to 
form Peyer’s patches [50–52]. The epithelium cover-
ing this intestinal lymphoid tissue displays phagocytic 
microfold cells (M-cells), whose specialized function is 
to absorb particulates from the intestinal lumen to be 
forwarded to the innate immune system including den-
dritic cells and macrophages [53]. Intestinal dendritic 
cells also reach out their membrane projections across 
the epithelial barrier into the gut lumen to take up par-
ticulates directly [54]. Thus,  TiO2 particle can be incor-
porated by cells of the innate immune system, where they 
persist without being substantially degraded or dissolved 
[16]. The local accumulation of such particles appears as 
pigments in the lymphoid tissue of the intestinal mucosa 
[51, 55–57].
Oral bioavailability in rodents
Inhalation studies in animals converge on the finding that 
nano-sized  TiO2 particles can enter, in small amounts, 
the systemic circulation from the alveolar epithelium and 
disseminate into other organs [21, 23, 58, 59]. Instead, 
dermal exposure studies indicated that  TiO2 particles of 
any size do not penetrate the stratum corneum of the skin 
[60–63]. Less certain is the extent of intestinal absorp-
tion, but an elegant vanadium (V) radiotracer study 
established that the vast majority of ingested  TiO2 nan-
oparticle is directly excreted in the feces. Briefly, com-
mercial anatase particles were irradiated with a proton 
beam to generate a radiolabeled  [48V]TiO2 fraction with 
a mean particle diameter of 50 nm. After demonstrating 
that most 48V ions remain associated with  TiO2 parti-
cles, a single dose (30–80 µg/kg body weight) of this test 
material was administered by intraesophageal instillation 
(oral gavage) to Wistar-Kyoto rats [64]. Groups of ani-
mals were sacrificed 1, 4, 24 h and 7 days after gavage to 
assess the transfer of radioactivity from the gastrointesti-
nal tract into the cardiovascular system and various tis-
sues. This time course revealed that a small proportion of 
the applied radioactivity (only ~ 0.6%) was detected in the 
blood and internal organs like liver, spleen and kidneys, 
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at 1 h after gavage. This overall proportion of systemically 
distributed  TiO2 particles gradually dropped to ~ 0.05% 
after 7 days.
Table  1 presents an overview of relevant oral expo-
sure studies in rodents found in the literature. A high-
dose biokinetic/acute toxicity study was carried out in 
CD-1 mice after a single administration by oral gavage 
of differentially sized  TiO2 particles (crystal structure 
not specified) administered at 5000  mg/kg body weight 
[42]. The mean diameter of the three tested particles was 
25 nm, 80 nm and 155 nm. Ti concentrations in tissues 
were determined by inductively coupled plasma (ICP)-
mass spectrometry 2  weeks after treatment. In animals 
that received the fine particles of 155  nm in diameter, 
increased Ti concentrations (~ 500 ng/g) over control lev-
els (< 100 ng/g) were found only in the spleen. For com-
parison, the highest Ti level (~ 4000  ng/g) was detected 
in the liver of animals that received the 80-nm particles. 
A major deficiency of this and other bioavailability stud-
ies is that distribution measurements rely on a chemical 
Ti analysis and, therefore, it is not clear whether the Ti 
detected in fluids and tissues is due to translocation of 
 TiO2 from the gastrointestinal tract in the form of par-
ticles or as solubilized material. A subsequent experi-
ment in CD-1 mice involved the oral administration by 
gavage of anatase particles with mean diameters of 18 
and 120  nm. The dose was 64  mg/kg body weight [65]. 
Increased Ti levels, measured by ICP-optical emission 
spectrometry, were detected in the blood, liver and pan-
creas, but only in animals administered the 18-nm par-
ticles. A peak Ti blood concentration of ~ 0.15  µg/ml 
(against a background of ~ 0.05 µg/ml) was detected 1 h 
after administration.
In an earlier study, Sprague–Dawley rats were treated 
with rutile particles (mean size of 500  nm) by oral gav-
age at a dose of 12.5  mg/kg body weight per day [66]. 
SEM analysis and histologic examination of tissues after 
10  days of dosing revealed the presence of  TiO2 parti-
cles in the GALT and mesenteric lymph nodes and even 
demonstrated some translocation to sinusoidal cells of 
the liver. The Ti content of the aforementioned tissues 
was demonstrated by ICP-atomic emission spectros-
copy and quantitative estimates suggested that approxi-
mately 6.5% of  TiO2 particles were absorbed. However, 
the authors did not consider the background Ti content 
in their calculations, likely resulting in an overestimation 
of systemic retention. In another study, Sprague–Dawley 
rats fed with Ti-free diet received by gavage a single oral 
dose of  TiO2 (5 mg/kg) in the form of nano- or micron-
sized particles with mean diameters ranging from 40 nm 
to 5  µm [40]. These particles consisted of anatase or 
rutile. Ti levels were measured by ICP-mass spectrom-
etry in the feces, blood and urine at different times after 
administration and no Ti translocation from the gastro-
intestinal tract into blood or urine was observed. The ani-
mals were sacrificed 4 days after administration for tissue 
analysis, but Ti concentrations in liver, spleen and kidney 
remained at control levels. In a subchronic study,  TiO2 
particles consisting of 80% anatase and 20% rutile (mean 
size of 26 nm) were administered orally to Sprague–Daw-
ley rats at daily doses of up to 1042 mg/kg body weight 
for 90  days [39]. Upon analysis by ICP-mass spectrom-
etry, no increased Ti levels were detected in liver, spleen, 
kidney and brain tissues even in the group of animals 
receiving the highest dose, thus indicating a very low oral 
bioavailability. In the blood taken at necropsy, the high 
background Ti concentration of ~ 0.4 µg/g was minimally 
increased, but only in males of the 521 and 1042-mg/kg 
groups.
Similar results were obtained from a study performed 
with differentially sized  TiO2 particles provided by the 
Joint Research Center (JRC) Nanomaterials Repository. 
These reference materials consist of anatase or rutile with 
mean particle sizes ranging from 6 to 90 nm. Wistar rats 
were administered these particles by oral gavage at a daily 
dose of around ~ 10 mg/kg body weight for 5 consecutive 
days [67]. The ICP-mass spectrometry analysis of liver, 
spleen and mesenteric lymph nodes performed 24 h after 
the last exposure revealed low Ti levels exceeding the 
limit of detection of 30  ng/g only occasionally. In a few 
 TiO2-exposed animals, there was a detectable but very 
slight increment of Ti in liver, spleen or the mesenteric 
lymph nodes. On the basis of these findings, the fraction 
of  TiO2 particles absorbed after repeated oral adminis-
tration was estimated to be maximally 0.02% by weight. 
Upon intravenous application, the same particles were 
predominantly retained in the liver, and the subsequent 
analysis of animals sacrificed at different times after 
injection reveled long half-lives of up to 650 days in the 
liver and spleen. It is therefore possible that even a lim-
ited systemic absorption from the gastrointestinal tract 
in combination with slow elimination might potentially 
result in tissue accumulation.
In a short-term exposure test, anatase particles (pri-
mary size of 20–60 nm) were administered by oral gavage 
to Sprague–Dawley rats at doses of up to 2 mg/kg body 
weight per day for five consecutive days [68]. ICP-mass 
spectrometry measurements revealed a slight but statisti-
cally significant increase of Ti concentrations relative to 
untreated controls not only in the spleen but surprisingly 
also in the ovaries of animals exposed at the higher dose. 
The penetration of  TiO2 into the spleen (but not into 
the ovaries) was confirmed by single-particle ICP-mass 
spectrometry and SEM analysis of tissue homogenates, 
thus demonstrating the presence of particle aggregates/
agglomerates.
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Table 1 Overview of oral toxicokinetic and toxicodynamic studies in rodents
Study type Oral dose Particle structure (mean 
size)
Internal exposure Main reported effects Source
Acute toxicity in mice 5000 mg/kg Structure not specified (25, 
80 and 155 nm)
~ 4 µg/g Ti in liver Histopathologic findings 
in brain, liver and kidney
[42]
Acute toxicity in rats Up to 5000 mg/kg Coated rutile/anatase 
(73 nm)
Not examined None [82]
Bioavailability in rats Up to 80 µg/kg Radiolabeled anatase 
(50 nm)
Oral particle bioavailability 
of ~ 0.6%
None [64]
Bioavailability in rats 5 mg/kg Anatase and rutile 
(40 nm–5 µm)
None detected None [40]
Toxicokinetics in rats ~ 10 mg/kg/day for 5 days Anatase and rutile 
(6–90 nm)
Oral particle bioavailability 
of ~ 0.02%
None [67]
Toxicokinetics in rats Up to 2 mg/kg/day for 
5 days
Anatase (20–60 nm) Increased Ti concentra-
tions in spleen and 
ovaries
Altered testosterone 
levels, histopathologic 
findings in thyroids
[68]
Toxicokinetics in rats Up to 30 mg/kg/day for 
7 days
Anatase and rutile (pri-
mary sizes not specified)
None detected None [37]
Toxicokinetics in rats 12.5 mg/kg/day for 
10 days
Rutile (500 nm) Detection of particles in 
GALT, lymph nodes and 
liver
None [66]
Subacute toxicity in mice Up to 500 mg/kg/day for 
5 days
Anatase/rutile (46 nm) Not examined Histopathologic findings 
in gut mucosa
[134]
Subacute toxicity in mice Up to 100 mg/kg/day for 
14 days
Anatase (20–50 nm) Not examined Histopathologic findings 
in liver
[83]
Subacute toxicity in mice 150 mg/kg/day for 14 days Anatase (21 nm) Not examined Histopathologic findings 
in liver
[84]
Subacute toxicity in rats 300 mg/kg/day for 14 days Structure not specified 
(50–100 nm)
Not examined Histopathologic findings 
in liver
[85]
Subacute toxicity in rats 24,000 mg/kg/day for 
28 days
Rutile (173 nm) Detection of particles in 
GALT
None [82]
Subacute toxicity in rats Up to 200 mg/kg/day for 
30 days
Anatase (75 nm) Not examined Histopathologic findings 
in liver
[88]
Subchronic toxicity in 
mice
Up to 250 mg/kg/day for 
42 days
Anatase (25 nm) Not examined Increased sperm abnor-
malities
[86]
Subchronic toxicity in 
mice
64 mg/kg/day for 196 days Anatase (18 and 120 nm) ~ 0.15 µg/ml Ti in whole 
blood
Histopathologic findings 
in liver, kidney, spleen 
and pancreas
[65]
Subchronic toxicity in rats Up to 1000 mg/kg/day for 
90 days
Coated rutile (145 nm) Detection of particles in 
GALT
None [82]
Subchronic toxicity in rats Up to 1042 mg/kg/day for 
90 days
Anatase/rutile (26 nm) Marginally higher Ti blood 
levels in males
None [39]
Subchronic toxicity in rats Up to 50 mg/kg/day for 30 
and 90 days
Anatase (24 nm) None Altered serum enzyme 
levels
[87]
Carcinogenicity in mice Up to 8350 mg/kg/day for 
2 years
Anatase (pigment-grade) Not examined Lower survival, hepatocel-
lular carcinomas
[112]
Carcinogenicity in rats Up to 2900 mg/kg/day for 
2 years
Anatase (pigment-grade) Not examined Hyperplastic bile ducts, 
thyroid carcinomas
[112]
Reproductive toxicity in 
rats
Up to 1000 mg/kg/day in 
gestation
Anatase and/or rutile 
(43–213 nm)
Not examined None [114]
Reproductive toxicity in 
rats
100 mg/kg/day in gesta-
tion
Anatase (10 nm) Increased Ti content in 
hippocampus
Impaired learning and 
memory
[116]
Acute colitis model in 
mice
Up to 500 mg/kg/day for 
7 days
Rutile (30–50 nm) Not examined Histopathologic findings 
in gut mucosa
[124]
Colon cancer model in rats Up to 10 mg/kg/day for 
up to 100 days
Anatase/rutile (22 and 
118 nm)
Detection of particles in 
GALT and liver
Histopathologic findings 
in gut mucosa
[135]
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Taken together, the above reports indicate a size-
dependent biokinetic behavior with low systemic absorp-
tion of orally administered fine-sized  TiO2 particles 
displaying primary sizes > 100 nm. This conclusion is con-
firmed by a toxicokinetic study in Sprague–Dawley rats 
carried out according to the OECD test guideline 417, 
which failed to detect any systemic uptake of pigment-
grade rutile and anatase particles [37]. Although some 
penetration may take place across and between entero-
cytes, the observed intestinal uptake of nano-sized  TiO2 
particles occurs primarily through the GALT as the port 
of entry [16, 53, 69]. Thus, a unique feature of the gas-
trointestinal exposure is that a fraction of  TiO2 particles 
is retained in the GALT from where the particles may 
reach the blood presumably through the lymphatic tho-
racic duct. There is finally only slow elimination of these 
particles from internal organs (with estimated half-lives 
of up 650  days), indicating the potential for persistence 
and accumulation after repeated uptake.
Oral bioavailability in humans
Studies in adult human subjects highlight a low but 
detectable oral bioavailability. Male volunteers ingested 
anatase particles at doses of 23 and 46 mg in gelatin cap-
sules (mean particle size of 160 nm) or as a powder (mean 
particle size of 380 nm) [70]. Pretreatment blood Ti lev-
els, measured by ICP-atomic emission spectroscopy, 
ranged between 0.007 and 0.02 µg/ml. After  TiO2 admin-
istration, blood was obtained at different times over 24 h. 
Around 8–12 h after the intake of 160-nm anatase at the 
dose of 23 mg (~ 0.4 mg/kg body weight), peak Ti concen-
trations in the blood reached 0.04–0.05 µg/ml in the five 
volunteers. The highest Ti concentration of 109.9  µg/l 
was detected in the blood of one volunteer 8  h after 
ingesting 46  mg (~ 0.75  mg/kg body weight) of 160-nm 
anatase. Administration of 380-nm anatase in the same 
amounts yielded lower blood concentrations. In another 
human study, nine volunteers received a 5-mg/kg single 
oral dose of different  TiO2 particles, i.e., anatase with a 
size of 15 nm, rutile with a size of ~ 100 nm and another 
rutile in the micron-scale range, dispersed in water [71]. 
The ICP-mass spectromety analysis of blood collected 
over a 4-day period, starting 24 h before dosing and end-
ing 3 days post-dose, revealed that essentially none of the 
administered particles were systemically absorbed. The 
background Ti concentration in the blood was 0.014 µg/
ml. A further study involved seven volunteers who 
ingested a single 100-mg dose of anatase (particle size of 
260 nm) in the form of gelatin capsules [72]. The parti-
cles were subsequently identified in the blood of by dark 
field microscopy and the presence of Ti was confirmed 
by ICP-mass spectrometry. A peak Ti blood concentra-
tion of ~ 10  µg/ml (against a background of ~ 1.5  µg/ml) 
was detected at 6 h after ingestion of the test item. Thus, 
this report presented by Pele et al. [72] not only confirms 
the earlier finding of Böckmann et al. [70] in revealing a 
peak of Ti in the blood after oral intake of  TiO2, but also 
demonstrates that at least part of this Ti appears in the 
blood as whole particles. There is an intriguing difference 
between the background Ti concentration of whole blood 
in most rodent studies (0.05  µg/ml or higher) and the 
lower levels observed in human blood (0.007–0.02  µg/
ml).
Impact of the particle corona
A critical aspect that has not yet been investigated with 
regard to bioavailability and systemic distribution is the 
effect of bound biomolecules that alter surface properties 
[73–75]. In fact, small particles avidly and rapidly adsorb 
on their surface macromolecules including proteins that 
modify key characteristics like their overall size, aggrega-
tion state, bioavailability, tissue distribution and bioaccu-
mulation. The term “corona” was introduced to describe 
the simultaneous attachment of multiple macromol-
ecules from a physiologic environment to the surface of 
nanoparticles [76, 77]. For example,  TiO2 particles incu-
bated in a simulated intestinal digestion juice form a 
corona of bile acids and proteins [78]. Also,  TiO2 nano-
particles incubated in blood plasma are readily decorated 
with a layer of proteins like apolipoprotein A-1, comple-
ment factors and immunoglobulins [73–75]. Thus, each 
biologic compartment has its own set of macromolecules 
that interact with outer particle surfaces. Although not 
explicitly tested, it can be assumed that  TiO2 adopts dis-
tinctive corona compositions in the context of each dif-
ferent food matrix in which this material is incorporated 
as additive [79]. Also, any given corona configuration is 
expected to progressively change upon oral ingestion, as 
the particles and surrounding food constituents move 
through saliva in the mouth to the gastric and intestinal 
fluids [80]. Presumably, the corona composition further 
changes if the particles move from the intestinal lumen 
to the central blood compartment and internal organs. 
A potential effect of this continuously changing corona 
is to modify key surface properties, which could medi-
ate particle transfer across biological barriers and their 
uptake into cells including for example macrophages, 
dendritic cells or hepatocytes, thus influencing bio-
availability and tissue permeability [81]. Importantly, 
the extent of macromolecular interactions and composi-
tion of the resulting corona depends on both the surface 
chemistry of the particles and their exact diameter. At 
the outer interface of nano-sized particles, for example, 
a highly curved surface increases the deflection angle 
between absorbed macromolecules, possibly leading to a 
higher density of such macromolecules in the corona of 
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smaller nanoparticles compared to the corona of larger 
particles [73–75]. Therefore, nanomaterial characteristics 
like surface chemistry and outer curvature determine the 
corona composition and these considerations imply that 
uncoated versus coated or small versus large particles 
exert fundamentally different biological effects as a con-
sequence of their distinct corona composition.
Acute toxicity
An overview of available toxicity studies is shown in 
Table  1. With the exception of genotoxicity tests, only 
the oral route of exposure is considered relevant for the 
risk assessment of  TiO2 as food additive. No mortality 
or adverse signs resulted from an acute exposure by sin-
gle oral gavage administrations of  TiO2 particles (crys-
tal structure not specified) according to the OECD test 
guideline 420. A suspension of the test material (mean 
particle size of 155  nm) was administered to male and 
female CD-1 mice at the dose of 5000  mg per kg body 
weight [42]. The same dose of nano-sized  TiO2 particles 
(diameters of 25 and 80 nm) resulted in an increased liver 
weight. There were also histopathologic findings in the 
brain (fatty degeneration of hippocampal regions), in the 
liver (hydropic degeneration around the central vein) and 
kidney (glomerular swelling). These organ damages were 
reportedly more serious in the animals treated with the 
80-nm particles, which is consistent with higher Ti tissue 
levels achieved by administration of these medium-sized 
test items compared to the 25 and 155-nm counterparts 
(see section on oral bioavailability above). No statisti-
cal analysis supported the causal relationship between 
histopathologic findings and  TiO2 treatments. For an 
acute oral toxicity study in Crl: CD(SD) rats according to 
OECD guideline 425, alumina- and silica-coated particles 
with a primary size of 73 nm and a crystalline composi-
tion of 79% rutile/21% anatase were administered by gav-
age at doses of up to 5000 mg/kg body weight [82]. These 
treatments with surface-coated particles failed to elicit 
mortality, biologically relevant body weight changes, 
clinical signs (except grey-colored feces) or gross organ 
lesions.
Subacute and subchronic toxicity
A subacute exposure was carried out in male albino 
mice with anatase particles displaying a primary size of 
20–50  nm (see Table  1 for an overview of oral toxicity 
studies). Daily doses of 10, 50 and 100 mg/kg body weight 
were applied for 14 consecutive days [83]. At the high-
est dose, this treatment induced a statistically significant 
increase of liver weight and histologic changes includ-
ing a recruitment of mononuclear cells to the vicinity of 
sinusoids accompanied by angiectasis (dilated sinusoi-
dal spaces filled with blood cells). Another 14-day oral 
exposure study was carried out in male albino mice with 
anatase particles displaying a mean diameter of 21  nm 
[84]. The particles were administered daily at 150 mg/kg 
body weight, leading to statistically significantly higher 
liver weights as well as significantly increased serum lev-
els of the liver enzymes alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST). The authors 
also reported histopathologic changes in the liver (focal 
degeneration of hepatocytes with mononuclear cell infil-
tration) supporting the hypothesis that the tested nano-
particles cause liver injury. Swelling and vacuolization 
of hepatocytes as well as infiltration of inflammatory 
cells were additionally detected in the liver of Wistar rats 
treated daily for 14 consecutive days by oral gavage with 
300 mg/kg  TiO2 particles (composition not specified, pri-
mary size of 50–100 nm) [85]. These adverse hepatocel-
lular effects were supported by a statistically significant 
increase of ALT, AST and alkaline phosphatase serum 
activity in treated animals compared to vehicle controls.
A 28-day study was carried out in line with OECD 
test guideline 407 using rutile particles with a mean size 
of 173  nm. This material was administered by oral gav-
age to 8-week old male Cr: CD(SD) rats at daily doses of 
24,000  mg/kg body weight [82]. One rat each from the 
control and test group died during the dosing period due 
to accidental perforation of the esophagus. There were, 
however, no test item-related effects on mortality, food 
intake, body weight, clinical signs, hematology, serum 
clinical chemistry, hematology, organ weights, gross 
pathology or histopathology. Brown granular aggregates 
or clumps, likely indicative for the presence of  TiO2, were 
seen upon hematoxylin and eosin staining in sections of 
the intestinal mucosa and draining lymphoid tissue, but 
without overt cellular reactions. These microscopic find-
ings related to the presence of test particles in the GALT 
were not considered to be adverse.
An oral subchronic (90-day) toxicity study was per-
formed in line with OECD test guideline 408 using rutile 
particles with a mean diameter of 145  nm. The particle 
surface was alumina-coated. This material was adminis-
tered to groups of 8-week old Cr: CD(SD) rats by daily 
gavage doses of up to 1000  mg/kg body weight [82]. 
There were no treatment-related effects on survival, food 
intake, body weight, clinical signs, hematology, clinical 
chemistry, hematology, organ weights, gross pathology 
or histopathology. Test material-related findings were 
limited to microscopic observations consistent with the 
oral route of uptake. In particular, granular aggregates 
or clumps, indicating the presence of  TiO2, were seen in 
the intestinal mucosa and the draining lymphoid tissue, 
without tissue reactions. Again, these findings related to 
the presence of  TiO2 particles in the GALT were not con-
sidered adverse. There is also a 28-week study with CD-1 
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mice exposed orally at 64 mg/kg/day to anatase particles 
with mean diameters of 18 and 120 nm [65]. The authors 
reported histopathologic findings such as tissue fractures 
in the liver, glomerular atrophy in kidneys and islet hya-
linization in the pancreas induced by 18-nm particles but 
not upon treatment with 120-nm particles, consistent 
with the missing systemic retention of the latter (see sec-
tion on oral bioavailability above).
In summary, these oral toxicity studies in rodents 
reveal major uncertainties limiting their predictive value 
for the risk assessment of human dietary exposure. Many 
reports are based on a small number of animals per treat-
ment group, involve an unusual or inadequate design or 
lack statistical analyses. Some studies used insufficiently 
characterized particles with regard to composition, pos-
sible contaminants, impurities or physico-chemical 
properties, and most reports failed to monitor particle 
size distributions. Single-dose [42] or repeated-dose oral 
exposures [83–85] point to liver toxicity as a common 
endpoint following gastrointestinal absorption of nano-
sized  TiO2 particles with mean diameters below 100 nm. 
This endpoint involving liver toxicity is not seen after 
oral administration of  TiO2 particles with mean diame-
ter above 100 nm [82]. Further adverse outcomes in oral 
toxicity studies were reported by the Medical College 
of Soochow University (Suzhou, China). These studies 
tested  TiO2 nanomaterials synthesized by technical pro-
cedures that are not consistent with commercial prod-
ucts in the food sector. Three of these studies indicating 
toxicity in animals were withdrawn by journal editors due 
to inadequate statistical analyses. As already pointed out 
[13, 29], the same methodological deficits are also found 
in other publications from the same group such that their 
reports were not further considered.
Oral toxicity in young animals
In view of the higher exposure of children relative to 
adults (see section on human exposure), it is also appro-
priate to screen the literature for oral toxicity studies car-
ried out in young laboratory animals. A seminal report 
involved pubertal male mice aged 4 weeks at the begin-
ning of exposure. Anatase particles with a mean diam-
eter of 25 nm were administered orally at daily doses of 
10, 50 and 250  mg/kg body weight for 42 consecutive 
days [86]. The analysis of epididymal sperm at the end 
of the exposure period revealed a statistically significant 
and dose-dependent increment of morphologic abnor-
malities. Although no changes in sperm number were 
detected, the fraction of sperm cells displaying abnor-
malities increased from ~ 13% in controls to ~ 23% in 
the 50-mg/kg group and ~ 29% in the 250-mg/kg group. 
These effects on spermatogenesis were associated, in 
the medium- and high-dose groups, with a reduction of 
serum testosterone levels, decreased layers of spermato-
genic cells and an increased appearance of vacuoles in 
the seminiferous tubules. No statistical evaluation of 
these histologic findings was given. The testosterone 
reduction described in the young mice of this report is 
contrasted by another study using 9–10-week old rats, 
described in more detail in the section on reproductive 
toxicity below, where anatase particles (primary size of 
20–60 nm) given by the oral route were associated with 
increased serum testosterone levels in males, whereas 
the concentration of this same hormone was reduced in 
females [68]. Another study focused on cardiac toxicity 
in young rats (4 weeks old at the beginning of the study) 
following 30 and 90 days of an oral exposure to anatase 
particles (mean size of 24  nm) at 2, 10 and 50  mg/kg 
body weight per day [87]. The authors report changes in 
some biochemical endpoints like decreased serum lac-
tate dehydrogenase, hydroxybutyrate dehydrogenase and 
creatine kinase activity in the high-dose group, but this 
study did not reveal any toxicologically relevant effects. 
A comparison between rats aged 4 weeks and rats aged 
9 weeks at the start of the study was carried out to test 
the susceptibility to anatase particles with a mean size 
of 75  nm [88]. Sprague–Dawley rats were administered 
daily doses at 10, 50 or 200  mg/kg body weight for 30 
consecutive days. Histologic examinations of the organs 
after the treatment period revealed changes in the liver 
described by the authors as hepatic cord disarray, peri-
lobular cell swelling, vacuolization and hydropic degen-
eration in both the 50 and 200-mg/kg dose groups, but 
only in young animals. These alterations were accompa-
nied by a statistically significant rise of serum bilirubin 
at the anatase dose of 200 mg/kg. In adult rats, less seri-
ous infiltrations of inflammatory cells in the liver paren-
chyma were seen at 10 and 50 mg/kg (but not at 200 mg/
kg) and considered to represent background liver lesions 
frequently observed in rats.
In summary, these few studies on the reaction of dif-
ferentially aged rodents suggest the possibility that young 
animals may be more susceptible than adults to develop-
ing adverse effects upon oral exposure to  TiO2 particles.
Genotoxicity
TiO2 particles with varying composition (anatase, rutile 
or mixtures of these two polymorphs) and different sizes 
were probed for mutagenicity in the canonical reverse 
mutation assay with bacteria (Ames test), usually at con-
centrations of up to 5–10  mg per standard plate. In all 
cases, the tested particles failed to elicit mutations in the 
absence or in the presence of rat liver microsomes medi-
ating metabolic activation (see for example [89–93]). 
However, the Ames test is not considered suitable for this 
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purpose due to the presumed inability of bacterial cells, 
conferred by their rigid cell wall, to take up the particles.
Conflicting findings were reported from in  vitro tests 
carried out in rodent or human cells and aimed at the 
detection of DNA strand breaks, point mutations, dele-
tions, chromosomal aberrations, micronuclei or sister 
chromatid exchanges. Mammalian cell-based genotox-
icity assays yielded both positive and negative outcomes 
when used to test  TiO2 particles. These methods include, 
in particular, single-cell electrophoresis (comet assays) as 
well as reporter gene, micronuclei, chromosomal aberra-
tion and sister chromatid exchange assays (see for exam-
ple [83, 91, 92, 94–107]). The interpretation of findings is 
uncertain because the effects, if any, may be secondary 
to cytotoxic or apoptotic reactions elicited by incubation 
of rodent or human cells with high concentrations of the 
test material.
For the evaluation of in vivo genotoxicity, it is impor-
tant to consider that, in view of the low absorption of 
 TiO2 particles after oral uptake (see section on oral bio-
availability), sufficient systemic exposure can only be 
achieved by parenteral administration. For example, 
B6C3F1 mice were subjected to daily intravenous injec-
tions of anatase particles (mean size of 10 nm) at doses 
ranging from 0.5 to 50 mg/kg body weight, for 3 consecu-
tive days. Genotoxicity was assessed by determining the 
micronuclei in reticulocytes and the frequency of muta-
tions in the X chromosome-linked phosphatidylinositol 
glycan complementation group A (Pig-A) gene in periph-
eral blood cells [108]. This study concluded that anatase 
nanoparticles reaching the bone marrow cause consider-
able cytotoxicity but without inducing direct genotoxic 
effects. Transgenic C57Bl/6 mice harboring the bacte-
rial lacZ reporter gene were injected intravenously with 
anatase particles (mean size of 22  nm) obtained from 
the JRC Nanomaterials Repository, at daily doses of up 
to 30  mg/kg body weight on 2 consecutive days [109]. 
No genotoxic effects were detected by scoring the fre-
quency of micronuclei in reticulocytes of the peripheral 
blood and by monitoring lacZ mutations as well as DNA 
strand breaks (by comet assay) in liver and spleen cells. 
Anatase/rutile particles (primary size of 21  nm) were 
injected intravenously to Wistar rats at a single dose of 
5 mg/kg body weight [110]. No genotoxicity was subse-
quently detected by analyzing bone marrow cells in the 
comet assay. A threefold increase in micronucleated 
cells was detected 1 h after the injection when polychro-
matic erythrocytes were stained with the conventional 
May-Grunwald-Giemsa reagents, but not in concomi-
tant stains with acridine orange. Although not recom-
mended by the relevant OECD test guideline 474, other 
authors selected the intraperitoneal route to expose rats 
with anatase/rutile particles displaying a primary size 
of 45  nm. The daily doses were 500–2000  mg/kg body 
weight applied for 5 consecutive days [111]. The animals 
were sacrificed 24  h after the last treatment and geno-
toxic effects were evaluated by counting the frequency 
of micronuclei in polychromated erythrocytes of the 
bone marrow, and by monitoring the appearance of DNA 
strand breaks when subjecting bone marrow, brain and 
liver cells to comet assays. These experiments revealed 
a statistically significant and dose-dependent increase in 
micronuclei and DNA strand breaks in response to the 
 TiO2 treatment. However, the report lacks an assessment 
of cytotoxicity in the tested tissues raising the possibility 
that the genotoxic effects might be secondary to particle-
induced cell death. The above considerations lead to the 
conclusion that there is no solid evidence for anatase/
rutile particles being genotoxic.
Carcinogenicity
Long-term (2-year) carcinogenicity studies were carried 
out in both B6C3F1 mice and Fisher 344 rats using, as the 
test material, pigment-grade anatase particles designated 
 Unitane® 0–220 [112]. The size of these test particles is 
not specified but it can be assumed from their optical 
properties that they have a mean diameter in the 200–
300  nm range conferring a white color. The test mate-
rial was included in the diet of mice (groups of 50 males 
and 50 females) at daily doses of 3250 and 6500  mg/kg 
body weight (for male animals) and 4175 and 8350 mg/
kg (for females). The particle-supplemented feed was 
not examined for possible nutritional imbalances. With 
the exception of white feces, there were no clinical signs 
related to  TiO2 administrations. The test item did not 
affect the survival of male mice but, in the females of the 
high-dose group, only 66% survival was reported until 
the end of the 104-week study compared to 90% survival 
in controls. No accompanying effects were reported that 
would explain this gender-specific difference. All sur-
viving animals were sacrificed after 103 weeks for com-
prehensive macroscopic and microscopic inspection for 
neoplasms. There was a dose-dependent increase in the 
incidence of hepatocellular carcinomas in males (17% of 
animals in the control group, 19% in the low-dose group 
and 29% in the high-dose group), although the test labo-
ratory noted that this higher occurrence of liver cancer 
remained within the range of historical reference con-
trols. The study authors, therefore, concluded that the 
oral  TiO2 administration is not carcinogenic in the tested 
mice strain.
In rats, the same  Unitane® 0–220 particles were 
tested by dietary administration to groups of 50 males 
and 50 females at daily doses of 1125 and 2250  mg/kg 
body weight (for males) and 1450 and 2900  mg/kg (for 
females). Again, the particle-supplemented feed was 
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not examined for possible nutritional imbalances. With 
the exception of white feces, there were no clinical signs 
related to  TiO2 exposure. The test substance had no effect 
on survival. After 103 weeks, the organs of surviving ani-
mals were subjected to macro- and microscopic analyses. 
There was an increased frequency of hyperplastic bile 
ducts in males of both the low- and high-dose groups. 
Tumor incidences in the treatment groups were report-
edly not higher than in controls. However, in females the 
combined incidence of c-cell adenomas and carcinomas 
of the thyroid was substantially increased from 2% in 
controls to 14% in the high-dose group. No such adeno-
mas or carcinomas were detected in the low-dose group. 
Although statistically significant by the Cochran–Armit-
age test (P = 0.013) and the Fisher exact test (P = 0.042), 
this increased neoplastic incidence was dismissed by 
introducing a Bonferroni correction for multiple com-
parisons. Irrespective of such statistical considerations, 
the emergence of thyroid tumors in rats needs careful 
considerations due to the questionable relevance of this 
finding for humans [113].
Reproductive toxicity
A pivotal prenatal developmental study evaluated three 
pigment-grade (pg-1, pg-2 and pg-3) and three ultrafine 
(uf-1, uf-2 and uf-3) anatase and/or rutile particles given 
to pregnant rats following the OECD test guideline 
414. The primary particle size was 153–213  nm for the 
pigment-grade material and 43–47  nm for the ultrafine 
material. These test substances were administered to 
Crl:CD(SD) rats by oral gavage on gestation days 6–20. 
Also, pregnant Wistar rats were exposed to  TiO2 parti-
cles (uf-2, pg-2 and pg-3) by oral gavage on gestation days 
5–19. The dose levels in both rat strains were 100, 300 
and 1000 mg/kg body weight per day [114]. At the end of 
each exposure period, the rats were sacrificed for caesar-
ean sections and examination of the dam and fetuses. As 
the only finding, at 1000 mg/kg per day, the uf-1 particles 
led to an increased fetal sex ratio (males/females) from 
0.46 in the controls to 0.60 in the treatment group. The 
range of the test facility historical control for this param-
eter was 0.43–0.53. Because the sex ratio is determined 
by events that occur around conception well before the 
start of the treatment on gestation day 6, the authors con-
cluded that this finding was not test item-related. These 
results are confirmed by a reproduction study according 
to OECD test guideline 421, which involved Sprague–
Dawley rats dosed with daily oral gavages of pigment-
grade  TiO2 at 1000 mg/kg body weight. The males were 
administered the test substance for 40  days (beginning 
from 2 weeks before the mating period) and females were 
treated for 2  weeks before mating, during the gestation 
period and until day 4 after delivery. Also this study did 
not reveal any reproductive or developmental toxicity 
[115].
Other reports ascribe adverse reproductive effects to 
orally administered  TiO2 particles but, unfortunately, 
these further experiments in rodents were not carried 
out following standardized procedures. Undoubtedly, 
these studies raise uncertainties but their impact on 
hazard identification and characterization is still limited 
in view of the small number of animals per treatment 
group, inappropriate study design or insufficient statisti-
cal analyses. In a study already mentioned in the preced-
ing sections, anatase particles (primary size of 20–60 nm) 
were given to Sprague–Dawley rats by the oral route at 
doses of up to 2  mg/kg body weight per day for 5 con-
secutive days [68]. This oral exposure was associated with 
increased serum testosterone levels in males, whereas the 
concentration of this hormone was reduced in females. 
The authors also reported histologic changes in the thy-
roid (desquamation into follicular lumen, follicles with 
irregular shape, smaller colloid space) after oral treat-
ments at 1 or 2 mg/kg body weight per day for 5 days.
Neurodevelopmental consequences of a  TiO2 exposure 
were suggested by a study in which pregnant Wistar rats 
were treated by oral gavage with anatase particles (pri-
mary size of 10 nm) at 100 mg/kg body weight [116]. This 
dose was applied daily from gestation day 2 to gestation 
day 21. Two male pups from each litter were sacrificed 
for the examination of brains immediately after birth. 
The Ti content in the hippocampus of the pups in the test 
group was increased to a statistically significant degree. 
Concomitantly, the authors observed that expression 
of the cell proliferation marker Ki67 is reduced in that 
brain region of treated animals relative to controls. On 
post-natal day 60, the learning and memory capacity was 
tested in randomly selected male pups by means of the 
passive avoidance and Morris water maze test, and was 
found to be impaired in the treatment group relative to 
controls.
Local effects in the gastrointestinal tract
Depending on the identified hazards, the usual risk 
characterization may need the assessment of additional 
endpoints that are not routinely inspected in the toxi-
cological evaluation of most chemicals. One question is 
whether  TiO2 particles may influence directly the bacte-
rial community in the gut lumen. When tested in  vitro 
using anaerobic reactors, which provide an intestinal 
microbiome surrogate, food-grade anatase has been 
shown to cause marginal shifts in bacterial populations, 
for example by slightly reducing the abundance of Bacte-
roides ovatus in favor of a Clostridium species as seen at 
particle concentrations of 100 µg/ml or higher [117, 118]. 
The biological relevance of these observations needs to 
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be ascertained but it appears so far that  TiO2 particles do 
not exert major effects on the human gut microbiota at 
realistic concentrations.
Another potential target of nanomaterials is the intes-
tinal surface under the surveillance of dendritic cells that 
act as first-line sentinels of foreign materials by filtering 
out a volume of up to 1500 µm3, which equals their own 
cell volume, per hour [119]. Unlike other antigen-pre-
senting cells, dendritic cells constitutively express class II 
major histocompatibility complexes and, in response to 
pathogen recognition, display co-stimulatory surface gly-
coproteins and secrete inflammatory cytokines. By these 
combined features, dendritic cells constitute key activa-
tors of both the innate and adaptive immune system [120, 
121]. It is not surprising to find that, based on their func-
tion in sampling their environment for intruding insults, 
dendritic cells are also able to capture nanoparticles 
in an efficient manner [122]. It was shown in  vitro that 
endotoxin-activated dendritic cells release the potent 
pro-inflammatory cytokine interleukin-1β (IL-1β) upon 
incubation with nano-sized anatase/rutile particles [123]. 
By activation of the inflammasome, leading to IL-1β 
secretion, gavage applications of rutile particles (30–
50 nm) at a daily dose of 50 mg/kg body weight aggravate 
macro- and microscopic signs of acute colitis induced in 
C57BL/6 mice by repeated exposures to dextran sulfate 
sodium (DSS) given in the drinking water [124]. In addi-
tion, a nano-Trojan horse hypothesis has been proposed 
due to the enhanced adsorptive surface property of nano-
particles and, hence, their potential to carry harmful sub-
stances as their cargo [125]. A relevant pro-inflammatory 
cargo of dietary inorganic particles like those containing 
 TiO2 consists of bacterial fragments such as lipopolysac-
charides (LPS) or peptidoglycan [126–128]. In this con-
text, pigment-grade  TiO2 particles have been shown to 
stimulate secretion of IL-1β from macrophages isolated 
from mice carrying a mutation in the nucleotide-binding 
oligomerisation domain-containing 2 (NOD2) gene [129], 
a mutation that confers an increased risk for inflamma-
tory bowel disease (IBD) [130, 131]. It is, therefore, pos-
sible that the binding of luminal antigens or adjuvants 
to  TiO2 particles could aid their delivery to inflamma-
tory cells of the gastrointestinal tract and contribute to 
the pathogenesis of IBD in susceptible individuals. Con-
versely, dietary nanoparticles by adsorptive sequestration 
on their surface may negatively influence the bioavailabil-
ity of iron, zinc and fatty acids [132, 133].
Reactions of the gastric mucosa were examined after 
oral treatment of Swiss Webster mice with nanopar-
ticles (mean size of 46  nm) composed of rutile (77%) 
and anatase (22%). The  TiO2 nanoparticles were dis-
persed in water and administered at daily doses of 5, 50 
and 500 mg/kg body weight for 5 consecutive days. The 
animals were sacrificed 24 h, 1 or 2 weeks after the last 
treatment. Analysis of the gastric epithelium by ICP-
mass spectrometry revealed a dose-dependent increase 
of Ti levels associated with histopathologic effects like 
submucosal edema, necrosis of epithelial cells and 
ulcerations [134]. The severity of these histopathologic 
findings increased with the dose. Another approach to 
this problem made use of a colorectal cancer model to 
test the ability of food-grade  TiO2 particles to acceler-
ate intestinal tumor progression. This murine model 
involves the intraperitoneal injection of the tumor ini-
tiator azoxymethane (AOM) combined with repeated 
exposures to the pro-inflammatory agent DSS in drink-
ing water. BALB/c mice were treated with the AOM/DSS 
protocol, with intragastric gavage of  TiO2 particles at 
5 mg/kg body weight per day alone, or with a combina-
tion of AOM/DSS and  TiO2 particles [18]. The primary 
size of these particles is not specified but TEM analyses 
revealed aggregates/agglomerates with diameters rang-
ing from 50 to 600 nm. The particle administrations took 
place during 5  days per week for 10  weeks. Necropsies 
carried out after 11 weeks revealed that the combination 
of AOM/DSS with  TiO2 particles increased the expres-
sion of markers of tumor progression (COX2, Ki67 and 
β-catenin) in the epithelium of the colon, whereas  TiO2 
alone did not induce such expression changes. Moreo-
ver, the authors observed that the tested food-grade  TiO2 
particles, even in the absence of any tumor initiator/pro-
moter, reduced the density of protective mucin-produc-
ing goblet cells detected by alcian blue staining.
The consequences of an oral exposure to food-grade 
 TiO2 on the intestinal mucosa was further investigated 
in male Wistar rats. Two types of anatase/rutile materi-
als were tested: commercial E 171 (primary particle size 
of 118  nm) and, as a reference, nanoparticles from the 
JRC Nanomaterials Repository (primary size of 22  nm). 
In a first experiment, these test materials were given by 
daily gavage administrations at 10  mg/kg body weight 
for 7  days in the absence of any additional treatment. 
In a second experiment, the animals were pretreated 
with the tumor initiator 1,2-dimethylhydrazine (DMH) 
followed by exposure to E 171 at daily doses of 0.2 and 
10 mg/kg body weight for 100 days through the drinking 
water. Another experimental group was exposed to E 171 
for 100 days without DMH pretreatment [135]. Interest-
ingly, exposure to E 171 in these experiments led to the 
internalization of light-diffracting particles not only in 
cells of the Peyer’s patches but, to a minor extent, also in 
the colonic mucosa and liver, particularly in proximity 
of the portal vein sinus. An accumulation of both E 171 
and  TiO2 nanoparticles in the Peyer’s patches of treated 
rats was confirmed by secondary ion mass spectrometry. 
Effects on the lymphoid tissue included an increased 
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number of dendritic cells in Peyer’s patches and a 
higher capacity of spleen cells to secrete cytokines like 
interferon-γ and IL-17, possibly dysregulating immune 
responses. In the carcinogenesis model, exposure to E 
171 at 10 mg/kg per day led to a statistically significant 
increase of aberrant crypt foci (defined as abnormal tube-
like glands in the lining of the colonic mucosa) regard-
less of whether the animals were pretreated with DMH 
or not. Based on these findings, the authors concluded 
that food-grade  TiO2 particles induce a low-grade local 
inflammation in the mucosa that has the potential to 
initiate preneoplastic lesions in the colonic mucosa. An 
important caveat in this interpretation of the reported 
findings is that the relevance of abnormal crypt foci as 
an early precursor of colorectal cancer is controversially 
discussed.
Conclusions
The Joint FAO/WHO Expert Committee on Food Addi-
tives considered unnecessary the establishment of an 
acceptable daily intake (ADI) for  TiO2 additives in food 
[136]. This decision was taken on the basis of the low 
solubility, poor absorption into internal organs like liver 
and the absence of acute toxic effects. Many reports pre-
sented in the context of this review suggest that, contrary 
to the assumptions made 50 years ago, food-grade  TiO2 
particles are not totally inert upon oral intake. The obser-
vation that  TiO2 particles cause at least some adverse 
reactions in experimental animals is disturbing because 
this material, including its unavoidable nano-scale 
byproducts, has been in use as food additive since 1966. 
The now available literature reveals data gaps and uncer-
tainties that should be addressed before declaring food-
grade  TiO2 particles as generally safe. A non-exhaustive 
list of such data gaps und uncertainties comprises the 
following.
  • Although there is only limited absorption from the 
gastrointestinal tract, toxicokinetic experiments 
in rats revealed very long tissue half-lives for  TiO2 
nanoparticles in internal organs [67]. This observa-
tion indicates that there is the potential for a slow but 
continued accumulation of particles upon lifelong 
exposure.
  • The public literature offers only one subchronic oral 
toxicity study in rodents carried out following inter-
nationally recognized OECD test guidelines [42]. 
This study was based on the daily administration of 
food-grade  TiO2 consisting of coated rutile particles. 
There were no test item-related adverse effects, yield-
ing a no observed effect level (NOEL) of 1000  mg/
kg body weight per day, which corresponds to the 
highest dose tested. By applying a default uncertainty 
factor of 200 (to adjust for inter-species as well as 
inter-individual variations in sensitivity, and for the 
extrapolation from subchronic to chronic exposure 
[137]), this NOEL of 1000  mg/kg/day translates to 
a tentative safe upper level for the lifetime intake of 
 TiO2 particles of 5 mg/kg body weight per day. How-
ever, the alumina-coated rutile under scrutiny is not 
at all representative for the full range of  TiO2 used 
in the food sector, which includes anatase or mixed 
anatase/rutile polymorphs, particularly also in an 
uncoated form.
  • Acute [42], subacute [83–85, 88], subchronic [42] and 
chronic toxicity studies [112] converge on the liver as 
a possible target organ for adverse effects after oral 
 TiO2 intake (Table  1). The carcinogenicity study in 
mice revealed an increased incidence of hepatocellu-
lar carcinomas in males at 6500 mg/kg/day (but not 
at 3250  mg/kg/day) compared to controls. The lack 
of genotoxicity of  TiO2 particles allows to assume a 
thresholded mode of liver cancer promotion and, by 
application of a default uncertainty factor of 100 (to 
adjust for inter-species and inter-individual varia-
tions in sensitivity [137]), the resulting no observed 
adverse effect level (NOAEL) of 3250  mg/kg/day 
translates to a tentative safe upper level for the life-
time intake of 3.25 mg/kg body weight per day. The 
subacute 30-day study by Wang et al. [88] identified 
a NOAEL for anatase nanoparticles in young animals 
of 10 mg/kg body weight per day. Assuming a nano-
particle fraction of 4.2% by weight [46], this value of 
10 mg/kg corresponds, in terms of food-grade  TiO2, 
to a NOAEL of 238.1 mg/kg body weight per day. By 
applying a default uncertainty factor of 600 (to adjust 
for inter-species as well as inter-individual variations 
in sensitivity, and for the extrapolation from 30 days 
to chronic exposure as proposed by Heringa et  al. 
[29]), the NOAEL of 238.1 mg/kg/day yields a tenta-
tive safe upper level for the intake of  TiO2 particles of 
0.40 mg/kg body weight per day.
  • One study suggests effects on spermatogenesis 
resulting in sperm abnormalities upon intragastric 
gavage administration of anatase nanoparticles for 
42 days [86]. This study was carried out in pubertal 
mice and is, therefore, relevant to address the pos-
sibly higher vulnerability of children. The NOAEL, 
as a nanoparticle dose, was 10  mg/kg body weight 
per day. Assuming as above a nanoparticle fraction 
of 4.2% by weight, this 10-mg/kg value corresponds 
again, in terms of food-grade  TiO2, to a NOAEL of 
238.1  mg/kg body weight per day. By applying a 
default uncertainty factor of 400 (to adjust for inter-
species as well as inter-individual variations in sen-
sitivity, and for the extrapolation from 42  days to 
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chronic exposure as proposed by Heringa et al. [29]), 
this NOAEL of 238.1  mg/kg/day yields a tentative 
safe upper level for the intake of  TiO2 particles of 
0.40 mg/kg body weight per day. Another study indi-
cates a penetration of  TiO2 nanoparticles into the 
ovaries from the gastrointestinal tract of rats [68]. A 
further report suggests neurodevelopmental distur-
bances upon exposure to  TiO2 nanoparticles during 
pregnancy in rats [116]. These findings, if confirmed, 
would raise additional concerns regarding the repro-
ductive safety.
  • There is finally only poor understanding of the con-
sequences of the proven uptake of  TiO2 by reac-
tive GALT cells, possibly triggering inflammatory 
responses that could favor chronic conditions like 
IBD, and perhaps leading to initiation, promotion 
and/or progression of neoplasms in the mucosa of 
the gastrointestinal tract [18, 134, 135]. Food-borne 
inorganic particles have been shown to accumulate 
during lifelong exposure in “pigment cells” of the 
GALT where the earliest signs of IBD are noted [126, 
138, 139]. This is a group of chronic conditions rang-
ing from Crohn’s disease (affecting all segments of 
the digestive tract) to ulcerative colitis (restricted to 
the large bowel) [140]. IBD has a multi-factorial etiol-
ogy with genetic susceptibility, gut microflora com-
position and a dysfunctional local immune reaction 
as main drivers [141]. Dietary factors have also been 
implicated in IBD and several authors raised the con-
cern that inorganic particles in food may contribute 
to initiating this chronic inflammatory condition by 
inappropriate stimulation of the innate immune sys-
tem [55, 56, 142, 143].
In conclusion, the existing toxicity studies cannot com-
pletely exclude human health risks from the long-term 
ingestion of  TiO2 particles. The above hypothetical upper 
safe levels for dietary intake (between 0.4 and 5  mg/kg 
body weight per day) calculated from rodent studies are 
in no way conclusive and are only meant to illustrate in 
quantitative terms the wide range of uncertainty in the 
current risk assessment of this ubiquitous food addi-
tive. Especially the estimated consumption by children 
suggests that, in any case, the dietary exposure to  TiO2 
particles should be reduced to remain, even in a worst-
case exposure scenario, below this proposed lowest safety 
threshold of 0.4 mg/kg daily. Further studies are needed 
to reduce existing uncertainties.
Recommendations
The uncertainty emerging in the retrospective assess-
ment of  TiO2 particles demonstrates the need for a fit-
to-purpose data requirement for the future evaluation 
not only of nano-sized but also of novel submicron-sized 
particles to be used as food additives. In particular, this 
review identified the following five main issues related 
to particles that resist rapid degradation or dissolution 
under digestive tract conditions:
  • To become eligible for the safety assessment, novel 
particles should first undergo a detailed characteri-
zation to provide unambiguous information on their 
constituents, structure and shape, surface character-
istics and coating, average size and size distribution, 
impurities, aggregation or agglomeration states. All 
these parameters should be specified with accompa-
nying analytical methods.
  • Particle characteristics like size, size distribu-
tion, crystalline form, shape and coating are critical 
determinants of intestinal uptake and adverse reac-
tions (see for example the above sections on particle 
corona and local gastrointestinal effects). Therefore, 
there is little opportunity for read-across proce-
dures to assess simultaneously multiple variants of 
the same particulate material. Instead, we advocate 
a case-by-case testing of particles with clearly estab-
lished specifications.
  • The potential genotoxicity of nano- and submicron-
size particles should be ruled out with mamma-
lian cell models and, pending on the findings, using 
in vivo genotoxicity tests with proven systemic expo-
sure, following generally recognized OECD guide-
lines.
  • In the absence of any evidence of genotoxicity, the 
safety testing should proceed with an extended 
90-day oral toxicity assay in rodents following OECD 
test guideline 408 [144], but with additional param-
eters for the detection of endocrine disruptors as 
listed in test guideline 407 [145]. This subchronic 
study should also include the analysis of tissues 
(including the GALT, mesenteric lymph node, spleen 
and liver) to examine the degree of systemic particle 
uptake. Such a toxicokinetic analysis should compare, 
if necessary using satellite groups of animals, the tis-
sue level of particles at an early and late time of the 
study to exclude a possible accumulation.
  • Additionally, more research is needed to under-
stand the consequences of interactions of indigest-
ible nano- and submicron-sized particles with the 
GALT and, in particular, with dendritic cells residing 
in the intestinal mucosa. As outlined in the section 
on local effects in the gastrointestinal tract, dendritic 
cells are the first-line sentinels of foreign materials as 
well as key activators of both the innate and adap-
tive immune system and, as such, potential triggers 
of particle-induced chronic inflammatory conditions.
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